Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, March 23, 2015, 74 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $987.00 to $64,149,572.70.

Highlighted Stocks Traded by Insiders:

Anacor Pharmaceuticals (ANAC) - FREE Research Report

Berns Paul L, who is President and CEO at Anacor Pharmaceuticals, sold 37,500 shares at $56.07 on March 23, 2015. Following this transaction, the President and CEO owned 308,760 shares meaning that the stake was reduced by 10.83% with the 37,500-share transaction.

The shares most recently traded at $54.80, down $1.27, or 2.32% since the insider transaction. Historical insider transactions for Anacor Pharmaceuticals go as follows:

  • 4-Week # shares sold: 9,600
  • 12-Week # shares sold: 10,800
  • 24-Week # shares sold: 73,248

The average volume for Anacor Pharmaceuticals has been 541,500 shares per day over the past 30 days. Anacor Pharmaceuticals has a market cap of $2.4 billion and is part of the health care sector and drugs industry. Shares are up 58.33% year-to-date as of the close of trading on Monday.

Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Currently, there are 4 analysts who rate Anacor Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ANAC - FREE

TheStreet Quant Ratings rates Anacor Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance and revenue growth. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full Anacor Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Agree Realty (ADC) - FREE Research Report

Hermiz Laith, who is Evp at Agree Realty, sold 3,000 shares at $33.50 on March 23, 2015. Following this transaction, the Evp owned 26,873 shares meaning that the stake was reduced by 10.04% with the 3,000-share transaction.

The shares most recently traded at $34.20, up $0.70, or 2.05% since the insider transaction. Historical insider transactions for Agree Realty go as follows:

  • 4-Week # shares bought: 28,000
  • 4-Week # shares sold: 3,305
  • 12-Week # shares bought: 28,000
  • 12-Week # shares sold: 3,305
  • 24-Week # shares bought: 28,000
  • 24-Week # shares sold: 3,305

The average volume for Agree Realty has been 127,100 shares per day over the past 30 days. Agree Realty has a market cap of $602.0 million and is part of the financial sector and real estate industry. Shares are up 10.23% year-to-date as of the close of trading on Monday.

Agree Realty Corporation, a real estate investment trust (REIT), engages in the ownership, development, acquisition, and management of retail properties, which are primarily leased to national and regional retail companies in the United States. The stock currently has a dividend yield of 5.27%. The company has a P/E ratio of 27.8. Currently, there are 3 analysts who rate Agree Realty a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ADC - FREE

TheStreet Quant Ratings rates Agree Realty as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in stock price during the past year, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Agree Realty Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

RadNet (RDNT) - FREE Research Report

Hames Norman R, who is Executive Vice President at RadNet, sold 46,390 shares at $7.75 on March 23, 2015. Following this transaction, the Executive Vice President owned 722,276 shares meaning that the stake was reduced by 6.04% with the 46,390-share transaction.

The shares most recently traded at $7.90, up $0.15, or 1.96% since the insider transaction. Historical insider transactions for RadNet go as follows:

  • 4-Week # shares sold: 35,000
  • 12-Week # shares sold: 35,000
  • 24-Week # shares sold: 180,839

The average volume for RadNet has been 337,500 shares per day over the past 30 days. RadNet has a market cap of $329.2 million and is part of the health care sector and health services industry. Shares are down 6.79% year-to-date as of the close of trading on Monday.

RadNet, Inc. provides outpatient diagnostic imaging services in the United States. The company has a P/E ratio of 251.3. Currently, there are 2 analysts who rate RadNet a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on RDNT - FREE

TheStreet Quant Ratings rates RadNet as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income and revenue growth. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full RadNet Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null